Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy.
OBJECTIVE
To assess prevention of bone mineral density (BMD) loss and durability of the response during treatment with prasterone in women with systemic lupus erythematosus (SLE) receiving chronic glucocorticoids.


METHODS
155 patients with SLE received 200 mg/day prasterone or placebo for 6 months in a double-blind phase. Subsequently, 114 patients were re-randomized to receive 200 or 100 mg/day prasterone for 12 months in an open-label phase. Primary efficacy endpoints were changes in BMD at the lumbar spine (L-spine) from baseline to Month 6 and maintenance of BMD from Month 6 to 18 for patients who received prasterone during the double-blind phase.


RESULTS
In the double-blind phase, there was a trend for a small gain in BMD at the L-spine for patients who received 200 mg/day prasterone for 6 months versus a loss in the placebo group (mean +/- SD, 0.003 +/- 0.035 vs -0.005 +/- 0.053 g/cm(2), respectively; p = 0.293 between groups). In the open-label phase, there was dose-dependent increase in BMD at the L-spine at Month 18 between patients who received 200 versus 100 mg/day prasterone (p = 0.021). For patients who received 200 mg/day prasterone for 18 months, the L-spine BMD gain was 1.083 +/- 0.512% (p = 0.042). There was no overall change in BMD at the total hip over 18 months with 200 mg/day prasterone treatment. The safety profile reflected the weak androgenic properties of prasterone.


CONCLUSIONS
This study suggests prasterone 200 mg/day may offer mild protection against bone loss in women with SLE receiving glucocorticoids. (ClinicalTrials.gov Identifiers NCT00053560 and NCT00082511).
Sánchez-Guerrero
Jorge
J
Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, México. jsanchezguerrero7@gmail.com
Fragoso-Loyo
Hilda E
HE
Neuwelt
C Michael
CM
Wallace
Daniel J
DJ
Ginzler
Ellen M
EM
Sherrer
Yvonne R S
YR
McIlwain
Harris H
HH
Freeman
Pamela G
PG
Aranow
Cynthia
C
Petri
Michelle A
MA
Deodhar
Atul A
AA
Blanton
Ellen
E
Manzi
Susan
S
Kavanaugh
Arthur
A
Lisse
Jeffrey R
JR
Ramsey-Goldman
Rosalind
R
McKay
James D
JD
Kivitz
Alan J
AJ
Mease
Philip J
PJ
Winkler
Anne E
AE
Kahl
Leslie E
LE
Lee
Albert H
AH
Furie
Richard A
RA
Strand
C Vibeke
CV
Lou
Lillian
L
Ahmed
Mumtaz
M
Quarles
Betty
B
Schwartz
Kenneth E
KE
D000328:Adult; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003687:Dehydroepiandrosterone / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced / Q000517:prevention & control*; D017698:Postmenopause
D050071:Bone Density Conservation Agents; D005938:Glucocorticoids; D003687:Dehydroepiandrosterone